Aromatherapy and menopausal mood: broad effects, thin certainty

Design

Systematic review and meta-analysis of randomised and quasi-experimental trials, GRADE-assessed

Population

1347 peri- and postmenopausal women across 17 studies

Primary outcome

Menopausal symptom scores, including anxiety and depression subscales

Effect

Depression SMD -0.57 (95% CI -0.85 to -0.28); anxiety SMD -0.63 (-1.10 to -0.16); no effect on urogenital symptoms

Menopausal transition brings vasomotor, sleep and mood symptoms together, and a good many women reach a psychiatrist rather than a gynaecologist with the mood component. This meta-analysis pooled 17 studies (21 reports, 1347 participants) of aromatherapy, including randomised trials and quasi-experimental designs.

The pooled estimates favour aromatherapy across almost everything measured: overall menopausal symptoms (SMD -1.00, 95% CI -1.43 to -0.58), vasomotor symptoms (SMD -0.79, -1.11 to -0.47), sleep quality (MD -3.95, -5.94 to -1.97), anxiety (SMD -0.63, -1.10 to -0.16) and depression (SMD -0.57, -0.85 to -0.28). Urogenital symptoms were the one outcome with no significant effect. GRADE certainty was low for most outcomes and very low for sleep and sexual function, and the authors decline to make a clinical recommendation on this basis.

A result that favours an intervention on every outcome at once should make you cautious rather than enthusiastic — it is the signature of small unblinded studies with subjective endpoints, which is what most of this pool is. The practical position is that a patient using lavender or similar alongside proper treatment is doing nothing harmful and may get some benefit for sleep and hot flushes; a patient offered it instead of an antidepressant or menopausal hormone therapy is being short-changed.

• Ask what over-the-counter or traditional remedies she is already using before adding anything.
• Treat aromatherapy as an adjunct to sleep and vasomotor management, not a mood treatment.
• Do not let a complementary trial delay assessment of a genuine depressive episode at menopause.
• Check for interactions where an essential-oil preparation is being taken orally rather than inhaled.

Why it matters

Patients are already using this; the question is whether it displaces treatment that works.

Don't overread it

Nearly all of these trials were unblinded with self-reported outcomes, which inflates apparent benefit.

The statistics, in plain English

A standardised mean difference of -0.57 for depression is a moderate effect on paper, but GRADE certainty of 'low' means the true effect could plausibly be much smaller or absent. Blinding is nearly impossible in an aromatherapy trial — the patient knows whether the room smells of lavender — so the measured benefit includes expectation. Uniform benefit across nine outcomes, with heterogeneity acknowledged as substantial, points to that rather than to a broadly effective therapy.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.